Group 1 | Group 2 | |||
---|---|---|---|---|

Carvedilol, Diltiazem, Isradipine, Mibefradil, Nicardipine, Quinidine, Ranolazine, Verapamil^{b} | Amiodarone, Felodipine, Nifedipine, Nitrendipine, Sertraline, Telmisartan, Troglitazone | |||

B>A | A>B | B>A | A>B | |

Cell-based | ||||

% t(2p*3p) > 3_{αβ} | 73 | 52 | 56 | 40 |

Average t(2p*3p)_{αβ}^{a} | 6.7 ± 3.1 | 5.6 ± 2.3 | 5.6 ± 2.7 | 5.9 ± 3.3 |

Vesicle-based | ||||

% t(2p*3p) > 3_{αβ} | 88 | 80 | ||

Average t(2p*3p)_{αβ}^{a} | 10.5 ± 6.5 | 7.5 ± 4.5 |

↵

*a*Average ± standard deviation for those compounds with t(2p*3p) > 3._{αβ}↵

*b*For the PCA analysis a complete set of IC_{50}values is needed from each participant. Therefore, the PCA analysis was limited to IC_{50}values from 8 inhibitors (group1) for a total of 24 data sets, using cell line-based as well as vesicle-based IC_{50}values. Group 2 comprises the remaining seven compounds